4 completed, 1 withdrawn. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Withdrawn 1 |
Follow BMS201038: new trials by email Literature Review of BMS201038 trials Research Report on BMS201038
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) Lomitapide - Homozygous Familial Hypercholesterolaemia (HoFH) | Phase 3 | Completed | Amryt Pharma | 46 | 2020-12-14 | 2025-08-27 |
| Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy Lomitapide - Homozygous Familial Hypercholesterolemia | Phase 3 | Withdrawn | Aegerion Pharmaceuticals, Inc. | 2016-05-01 | 2018-02-22 | |
| Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy lomitapide - Familial Hypercholesterolemia - Homozygous | Phase 3 | Completed | Aegerion Pharmaceuticals, Inc. | 9 | 2014-04-02 | 2018-10-10 |
| Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia lomitapide - Familial Hypercholesterolemia | Phase 3 | Completed | Aegerion Pharmaceuticals, Inc. | 19 | 2009-10-29 | 2018-06-13 |
| A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) AEGR-733 - Homozygous Familial Hypercholesterolemia | Phase 3 | Completed | Aegerion Pharmaceuticals, Inc. | 29 | 2007-12-01 | 2018-03-20 |
Homozygous Familial Hypercholesterolemia (5) · Hypercholesterolemia (1) · Hyperlipoproteinemia Type II (1)
Aegerion Pharmaceuticals, Inc. (4) · Amryt Pharma (1)
Italy (3) · Canada (2) · South Africa (2) · United States (2) · Germany (1) · Israel (1) · Japan (1) · Saudi Arabia (1) · Spain (1) · Tunisia (1)
Marina Cuchel, MD, PhD (2) · Mark Sumeray, MD (2) · Mariko Harada-Shiba, M.D., Ph.D. (1)